The integration sites at the two hotspots, chr1: 34,397,059 (CSMD2) and chr8:118,557,327 (MED30/EXT1), were not reported in previous HBV integration studies (except in this dataset as we previously reported [42]), but overlapped with multiple fusion events from both cancer cell lines and TCGA [65] (Additional file 13: Table S12). The gene discussed is MED30; the disease is cancer.